|  |  |  |
| --- | --- | --- |
| Will my taking part in the trial be kept confidential? In this research trial we will use information from you and your medical records. We will only use information that we need for research and safety purposes. We will let very few people know your name or contact details, and only if they really need it for this trial. Everyone involved in this trial will keep your data safe and secure. We will also follow all privacy rules.  At the end of the trial, we will save some of the data in case we need to check it and for future research. We will make sure no-one can work out who you are from the reports we write.  The full Participant Information Sheet tells you more about this.  AIR-NET Brief Participant Information Sheet V1 26-07-24  IRAS Ref: 1010124  Page 1 of 2 | The AIR-NET Trial If you are interested in taking part in this trial or would like any more information, please contact the trial team by:  Calling Researcher:  [LOCAL RESEARCHER]  Or  E-mail: [LOCAL RESEARCHER]  We will discuss the trial further and send you a full information sheet. Your local Investigator for the trial is: Principal Investigator:  [LOCAL PI]  [ADDRESS]  [PHONE NUMBER]  [EMAIL] The AIR-NET Trial **Testing anti-inflammatories for the treatment of bronchiectasis**  IRAS Ref: 1010124 | LOCAL NHS LOGO A blue rectangle with text  Description automatically generated Testing anti-inflammatories for the treatment of bronchiectasisDo you have bronchiectasis?You may be able to take part in a research trial |

|  |  |  |
| --- | --- | --- |
| What is the trial about? People with bronchiectasis frequently get chest infections which are difficult to treat and can cause coughing, sputum (phlegm) production, breathlessness and tiredness. Symptoms of bronchiectasis are caused by inflammation in the lungs.  The purpose of this trial is to test if anti-inflammatory medications can be used to treat bronchiectasis. The medications being tested are already used to treat other medical conditions.  The main aims of this trial are to find out:  If anti-inflammatory medications reduce lung inflammation in bronchiectasis?  If these medications can be taken safely by people who have bronchiectasis?  If any of these medications improve quality of life for people living with bronchiectasis?  We will compare people who have been given an anti-inflammatory medication with people who continue with their usual bronchiectasis treatment. | What is involved? Participation in the trial is entirely voluntary and you may withdraw at any time. You will be asked to attend the hospital 6times over a 3-month period. Each visit will take between 1 ½ - 2 ½ hours. A £100 payment will be provided for each visit you attend.  At each visit you will be seen by a Researcher. Each visit will involve a health check, monitoring of your symptoms, and trial assessments. You will have some blood samples and sputum samples collected. You will also be asked to complete questionnaires and a patient symptom diary.  You will be allocated to receive one of four treatments for 28 days:   * Usual care (no change to treatment) * Disulfiram (an anti-inflammatory) * Dipyridamole (an anti-inflammatory) * Doxycycline (an anti-inflammatory)   You will not be able to choose which trial treatment you are given; this will be decided randomly. You will be told which treatment you have been allocated to. | What are the possible benefits of taking part? By taking part you are contributing to medical science. The results may help other people with bronchiectasis in the future. Your health will be closely monitored throughout the trial. What are the possible disadvantages and risks of taking part? The anti-inflammatory medications are already used for other health conditions and have been used safely. The full Participant Information Sheet has all the details about each trial medication. Who has reviewed the trial? Patient partners from the European Lung Foundation have helped us develop the trial and the Participant Information Sheets.  The XXXXX Ethics Service has examined this trial and has raised no objections from the point of view of medical ethics.  AIR-NET Brief Participant Information Sheet V1 26-07-24  Page 2 of 2 |